Table 3 Actuarial and estimated cancer-related outcome in the study and control group
|  | All patients % (n = 212) | Study group with neoadjuvant treatment % (n = 106) | Control group without neoadjuvant treatment % (n = 106) | p-value |
|---|---|---|---|---|
Follow-Up in years (mean) | 4.04 | 4.3 ± 2.55 | 3.8 ± 3.05 | 0.172 |
Actuarial outcome | Â | Â | Â | Â |
Cancer related survival | Â | Â | Â | Â |
 All UICC stages | 69.8 | 67.9 | 71.7 | 0.65 |
 UICC stage 0-III | 86.4 | 82.7 | 90.1 | 0.25 |
Disease free survival | Â | Â | Â | Â |
 UICC stage 0-III | 76.5 | 70.4 | 82.7 | 0.09 |
Local recurrence | Â | Â | Â | Â |
 All UICC stages | 5.2 | 5.7 | 4.7 | 1.00 |
 UICC stage 0-III | 6.8 | 7.4 | 6.2 | 1.00 |
Estimated 5-year outcome | Â | Â | Â | Â |
Cancer related survival | Â | Â | Â | Â |
 All UICC stages | 67.3 | 66.7 | 67.9 | 0.88 |
 UICC stage 0-III | 85.8 | 82.0 | 89.6 | 0.32 |
Disease free survival | Â | Â | Â | Â |
 UICC stage 0-III | 73.3 | 66.7 | 79.9 | 0.22 |
Local recurrence | Â | Â | Â | Â |
 All UICC stages | 8.4 | 9.0 | 7.8 | 0.98 |
 UICC stage 0-III | 8.5 | 9.2 | 7.9 | 0.95 |